Recombinant Human AFMID Protein, MYC/DDK-tagged
Cat.No. : | AFMID-546H |
Product Overview : | Recombinant Human AFMID fused with MYC/DDK tag at C-terminal was expressed in HEK293. |
- Specification
- Gene Information
- Related Products
Source : | HEK293 |
Species : | Human |
Tag : | MYC/DDK |
Form : | 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol. |
Molecular Mass : | 33.8 kDa |
Purity : | > 80% as determined by SDS-PAGE and Coomassie blue staining |
Concentration : | >50 ug/mL as determined by microplate BCA method |
Gene Name : | AFMID arylformamidase [ Homo sapiens ] |
Official Symbol : | AFMID |
Synonyms : | KF |
Gene ID : | 125061 |
mRNA Refseq : | NM_001010982 |
Protein Refseq : | NP_001010982 |
UniProt ID : | Q63HM1 |
Products Types
◆ Recombinant Protein | ||
AFMID-92H | Recombinant Human AFMID Protein, His&GST-tagged | +Inquiry |
Afmid-1549M | Recombinant Mouse Afmid Protein, Myc/DDK-tagged | +Inquiry |
AFMID-378M | Recombinant Mouse AFMID Protein, His (Fc)-Avi-tagged | +Inquiry |
AFMID-288H | Recombinant Human AFMID Protein, His (Fc)-Avi-tagged | +Inquiry |
AFMID-2437Z | Recombinant Zebrafish AFMID | +Inquiry |
◆ Lysates | ||
AFMID-14HCL | Recombinant Human AFMID lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (20)
Ask a questionDysregulation or dysfunction of AFMID protein is implicated in human diseases, and associations can be investigated using disease models, patient samples, or genetically modified systems, combined with phenotypic assessments or molecular analysis techniques.
The enzymatic activity of AFMID protein can be measured or characterized using biochemical assays or enzymatic activity assays specific to its function.
AMDHD1 possesses enzymatic activity, such as hydrolase or esterase activity, and exhibits specificity towards specific lipid substrates.
AFMID protein can be targeted or modulated to manipulate specific metabolic pathways or alleviate disease conditions, and its therapeutic potential can be evaluated using in vitro or in vivo models, combined with functional assays or disease outcome measures.
Modulating AMDHD1 activity or expression may hold therapeutic potential for metabolic disorders, providing opportunities for developing interventions that target lipid metabolism or oxidative stress-related pathways.
AFMID protein influences downstream metabolic pathways or cellular processes, which can be investigated through metabolomic profiling, genetic or pharmacological perturbations, or functional assays specific to the pathways of interest.
AMDHD1 interacts with other proteins involved in lipid metabolism, such as enzymes or transporters, and these interactions modulate cellular processes such as lipid synthesis, degradation, or transport.
AMDHD1 expression is regulated at transcriptional and post-transcriptional levels, influenced by hormonal signals, nutritional status, or cellular stresses.
AMDHD1 exhibits a tissue-specific expression pattern, with higher levels observed in tissues with active lipid metabolism, suggesting its involvement in lipid-related processes.
The enzymatic function and protein interactions of AMDHD1 are dependent on its unique structural features, including catalytic residues and protein interaction domains.
AFMID protein participates in cellular redox balance or oxidative stress response, and its involvement in these processes can be investigated using techniques such as redox assays, ROS detection, or genetic manipulations combined with functional assessments.
AMDHD1 plays a role in lipid metabolism by participating in the breakdown or remodeling of specific lipid molecules, contributing to lipid homeostasis.
The structural features or domains of AFMID protein contribute to its enzymatic activity or substrate specificity, and their functional roles can be investigated using techniques such as protein structure determination, site-directed mutagenesis, or biochemical assays.
The expression of AFMID protein is regulated by specific factors and signaling pathways that control its transcriptional or post-transcriptional regulation.
AMDHD1 deficiency or dysregulation may lead to altered lipid metabolism, mitochondrial dysfunction, or cellular stress, potentially contributing to metabolic disorders or other related diseases.
Genetic variations or mutations in the gene encoding AFMID protein may impact its expression or function, leading to altered susceptibility to diseases or metabolic disorders, and these can be studied through genetic association studies or functional characterization of mutant variants.
AFMID protein interacts with endogenous substrates or metabolites, and their interactions can be studied or quantified using techniques such as mass spectrometry, metabolomics analysis, or enzymatic assays.
AMDHD1 contributes to maintaining cellular redox balance by participating in lipid metabolism pathways linked to antioxidant defense mechanisms.
AMDHD1 activity can influence downstream signaling pathways, including those involved in lipid signaling, cellular energy homeostasis, or inflammation.
Post-translational modifications or regulatory mechanisms may modulate the activity or stability of AFMID protein, and these can be studied using techniques such as site-directed mutagenesis, phosphoproteomics analysis, or biochemical assays.
Customer Reviews (3)
Write a reviewUnraveling protein-protein interactions in lipid metabolism for metabolic disorders.
Elucidating protein-protein interactions in cell adhesion for tissue morphogenesis.
Exploring protein-protein interactions in neurodegenerative diseases for therapeutic targets.
Ask a Question for All AFMID Products
Required fields are marked with *
My Review for All AFMID Products
Required fields are marked with *
Inquiry Basket